CN118451511A - 协变量校正来自不同药物使用模式的表型测量的时间数据 - Google Patents

协变量校正来自不同药物使用模式的表型测量的时间数据 Download PDF

Info

Publication number
CN118451511A
CN118451511A CN202280086064.0A CN202280086064A CN118451511A CN 118451511 A CN118451511 A CN 118451511A CN 202280086064 A CN202280086064 A CN 202280086064A CN 118451511 A CN118451511 A CN 118451511A
Authority
CN
China
Prior art keywords
time point
drug
phenotypic
computer
implemented method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280086064.0A
Other languages
English (en)
Chinese (zh)
Inventor
P·P·菲齐耶夫
J·F·麦克雷
K-H·法尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inmair Ltd
Original Assignee
Inmair Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inmair Ltd filed Critical Inmair Ltd
Priority claimed from PCT/US2022/054196 external-priority patent/WO2023129622A1/en
Publication of CN118451511A publication Critical patent/CN118451511A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40—Population genetics; Linkage disequilibrium
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/10—Boolean models
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Chemical & Material Sciences (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Databases & Information Systems (AREA)
  • Primary Health Care (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Software Systems (AREA)
  • Artificial Intelligence (AREA)
  • Evolutionary Computation (AREA)
  • Pathology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Ecology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
CN202280086064.0A 2021-12-29 2022-12-28 协变量校正来自不同药物使用模式的表型测量的时间数据 Pending CN118451511A (zh)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US202163294820P 2021-12-29 2021-12-29
US202163294828P 2021-12-29 2021-12-29
US202163294816P 2021-12-29 2021-12-29
US202163294813P 2021-12-29 2021-12-29
US202163294830P 2021-12-29 2021-12-29
US202163294827P 2021-12-29 2021-12-29
US63/294828 2021-12-29
US63/294830 2021-12-29
US63/294820 2021-12-29
US63/294816 2021-12-29
US63/294813 2021-12-29
US63/294827 2021-12-29
US202263351299P 2022-06-10 2022-06-10
US202263351283P 2022-06-10 2022-06-10
US202263351317P 2022-06-10 2022-06-10
US63/351299 2022-06-10
US63/351317 2022-06-10
US63/351283 2022-06-10
US17/968766 2022-10-18
US17/968,766 US20230207132A1 (en) 2021-12-29 2022-10-18 Covariate correction including drug use from temporal data
PCT/US2022/054196 WO2023129622A1 (en) 2021-12-29 2022-12-28 Covariate correction for temporal data from phenotype measurements for different drug usage patterns

Publications (1)

Publication Number Publication Date
CN118451511A true CN118451511A (zh) 2024-08-06

Family

ID=86896998

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202280086064.0A Pending CN118451511A (zh) 2021-12-29 2022-12-28 协变量校正来自不同药物使用模式的表型测量的时间数据
CN202280086055.1A Pending CN118475982A (zh) 2021-12-29 2022-12-28 罕见变体多基因风险评分
CN202280086049.6A Pending CN118451506A (zh) 2021-12-29 2022-12-28 基于最大限度地分离携带者和非携带者的嵌套t检验的优化的负荷检验

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202280086055.1A Pending CN118475982A (zh) 2021-12-29 2022-12-28 罕见变体多基因风险评分
CN202280086049.6A Pending CN118451506A (zh) 2021-12-29 2022-12-28 基于最大限度地分离携带者和非携带者的嵌套t检验的优化的负荷检验

Country Status (7)

Country Link
US (3) US20230207132A1 (cg-RX-API-DMAC7.html)
EP (5) EP4457829B1 (cg-RX-API-DMAC7.html)
JP (3) JP2025502816A (cg-RX-API-DMAC7.html)
KR (3) KR20240124391A (cg-RX-API-DMAC7.html)
CN (3) CN118451511A (cg-RX-API-DMAC7.html)
AU (3) AU2022426690A1 (cg-RX-API-DMAC7.html)
CA (2) CA3242597A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120977385A (zh) * 2025-10-20 2025-11-18 浙江博圣生物技术股份有限公司 一种单基因遗传病致病突变的打分排序方法及系统

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1301633A1 (en) * 2000-07-21 2003-04-16 Althea Technologies, Inc. A systematic approach to mechanism-of-response analyses
WO2014110350A2 (en) * 2013-01-11 2014-07-17 Oslo Universitetssykehus Hf Systems and methods for identifying polymorphisms
CN111161799B (zh) * 2019-12-24 2023-12-15 大连海事大学 一种基于多组学数据获取多基因风险评分的方法及系统
WO2022020444A1 (en) * 2020-07-22 2022-01-27 Algen Biotechnologies, Inc. Methods and systems for determining drug effectiveness

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120977385A (zh) * 2025-10-20 2025-11-18 浙江博圣生物技术股份有限公司 一种单基因遗传病致病突变的打分排序方法及系统
CN120977385B (zh) * 2025-10-20 2026-02-06 浙江博圣生物技术股份有限公司 一种单基因遗传病致病突变的打分排序方法及系统

Also Published As

Publication number Publication date
EP4457829C0 (en) 2026-02-04
EP4715828A2 (en) 2026-03-25
AU2022426690A1 (en) 2024-07-04
EP4457829B1 (en) 2026-02-04
US20230207052A1 (en) 2023-06-29
US20230207067A1 (en) 2023-06-29
KR20240131385A (ko) 2024-08-30
CN118451506A (zh) 2024-08-06
EP4457819A1 (en) 2024-11-06
KR20240124391A (ko) 2024-08-16
CN118475982A (zh) 2024-08-09
EP4742250A2 (en) 2026-05-13
EP4457818B1 (en) 2025-12-24
EP4457818C0 (en) 2025-12-24
JP2025502818A (ja) 2025-01-28
CA3242597A1 (en) 2025-02-26
JP2025502816A (ja) 2025-01-28
US20230207132A1 (en) 2023-06-29
JP2025502817A (ja) 2025-01-28
AU2022429829A1 (en) 2024-07-04
EP4457818A1 (en) 2024-11-06
EP4457829A1 (en) 2024-11-06
EP4715828A3 (en) 2026-06-17
AU2022425376A1 (en) 2024-06-27
KR20240124390A (ko) 2024-08-16
CA3242710A1 (en) 2023-07-06
EP4742250A3 (en) 2026-07-22

Similar Documents

Publication Publication Date Title
CN113597645B (zh) 用于重建药物应答和疾病网络的方法和系统以及其用途
Ching et al. Opportunities and obstacles for deep learning in biology and medicine
Gao et al. EpiGePT: a pretrained transformer-based language model for context-specific human epigenomics
WO2023129621A1 (en) Rare variant polygenic risk scores
Azuaje Bioinformatics and biomarker discovery:" omic" data analysis for personalized medicine
Maguluri et al. Big Data Solutions For Mapping Genetic Markers Associated With Lifestyle Diseases
Xiong et al. scGHOST: identifying single-cell 3D genome subcompartments
US20230410941A1 (en) Identifying genome features in health and disease
Du et al. Enhancing recognition and interpretation of functional phenotypic sequences through fine-tuning pre-trained genomic models
JP2025527970A (ja) 極端なレベルの遺伝子発現を引き起こす希少バリアントを同定するコンピュータ実施方法
CN118946932A (zh) 在碱基分辨率下基于人工智能的基因保守性和表达保留检测
EP4457829B1 (en) Covariate correction for temporal data from phenotype measurements for different drug usage patterns
US20220293214A1 (en) Methods of analyzing genetic variants based on genetic material
Martins et al. Enhancing schizophrenia phenotype prediction from genotype data through knowledge-driven deep neural network models
Quan et al. Learning useful representations of DNA sequences from ChIP-seq datasets for exploring transcription factor binding specificities
WO2023129622A1 (en) Covariate correction for temporal data from phenotype measurements for different drug usage patterns
WO2023129619A1 (en) Optimized burden test based on nested t-tests that maximize separation between carriers and non-carriers
Arulanandham et al. Role of Data Science in Healthcare
Mohammed et al. Enhancing Hypertrophic Cardiomyopathy Heart Risk Assessment with Deep Learning and Multi-Omics Data Integration
Mamidi Improving Molecular Diagnosis Success Rates and Prognosis Prediction for Patients With Rare Diseases
Xian Use of the Electronic Health Records to facilitate phenotyping, comorbidity analysis, and genomics
Stetter et al. GeneSim™: Intelligent IT Platform for the Biomedical World
Balis Machine Learning Tools, Models, and Algorithms for Early Detection of Alzheimer’s Disease in Correlation with Multi Omics Data

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination